Associated tags: Therapy, Knowledge, Intelligence, Mayo Clinic, Software, Health, Research, Data Management, Cardiology, Biotechnology, Artificial Intelligence, Science, Pharmaceutical industry, Infectious Diseases, Medical device, Hospitals, Patient, Medical Devices, FDA, Algorithm, AI, Health Technology
Locations: TENNESSEE, GEORGIA, LONDON, UNITED STATES, NORTH AMERICA, ILLINOIS, MASSACHUSETTS, CHICAGO, MINNESOTA, INDIA, CANADA
Software,
Research,
General Health,
Data Management,
Oncology,
Technology,
Genetics,
Artificial Intelligence,
Health Technology,
Clinical Trials,
Science,
Biotechnology,
Health,
Patient,
Infection,
Progression-free survival,
Data,
Immunology,
Algorithm,
DSM-IV codes,
Breast cancer,
Gastroenterology,
AI,
Pramana,
Cancer,
EHR,
ASCO,
Natural language processing,
Poster,
Society,
Cardiology,
Annual general meeting,
Medical imaging nference , a company dedicated to transforming healthcare by making biomedical data computable, will present research at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 to June 4 in Chicago.
Key Points:
- nference , a company dedicated to transforming healthcare by making biomedical data computable, will present research at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 to June 4 in Chicago.
- "This recent study demonstrates how AI and real-world data can drive innovation in oncology, enabling more precise and efficient cancer care and research."
- Results showed 99.8% sensitivity and 98.2% accuracy at the sentence level, and 92.5% sensitivity and 88.0% accuracy at the patient level.
- A second abstract was accepted by ASCO for online publication, titled Clinical nSights: A software platform to accelerate real world oncology analyses .
Health,
Medical Devices,
Technology,
Health Technology,
Software,
Artificial Intelligence,
Cardiology,
Brandeis University,
Cardiac amyloidosis,
CFO,
Heart,
Algorithm,
Therapy,
FDA,
Category,
International Business School,
American Medical Association,
Traction,
AI,
Growth,
Acquisition,
Hyperkalemia,
Pulmonary hypertension,
Medtech,
Infection,
Copenhagen Business School Anumana , a leading AI-driven health technology company and portfolio company of nference , today announced the appointment of Harry S. Palmin as chief financial officer (CFO).
Key Points:
- Anumana , a leading AI-driven health technology company and portfolio company of nference , today announced the appointment of Harry S. Palmin as chief financial officer (CFO).
- In his new role, he will lead financial operations, investor relations, and corporate development activities at Anumana, and guide the company’s strategic growth.
- In addition to his role as CFO of Anumana, Palmin joins nference as CFO, Ventures.
- “Harry is a highly skilled and accomplished executive with a proven track record in building successful companies in the life sciences industry,” said Maulik Nanavaty, CEO of Anumana.
Retrieved on:
Tuesday, February 6, 2024
Technology,
Managed Care,
Infectious Diseases,
Foundation,
Philanthropy,
Hospitals,
Science,
Clinical Trials,
Biotechnology,
Health,
Other Philanthropy,
Other Science,
Research,
Software,
Other Health,
Data Management,
Artificial Intelligence,
Health equity,
Bill,
Melinda French Gates,
Pramana,
Pharmaceutical industry nference , a company dedicated to transforming healthcare by making biomedical data computable, today announced a multi-year licensing agreement with the Bill & Melinda Gates Foundation.
Key Points:
- nference , a company dedicated to transforming healthcare by making biomedical data computable, today announced a multi-year licensing agreement with the Bill & Melinda Gates Foundation.
- This collaboration provides the Gates Foundation access to nference's nSights platform, where researchers can access a repository of extensive clinical data and expertise from top-ranked medical institutions.
- The nSights platform, leveraging nference’s federated network, will provide resources to help the Gates Foundation more easily visualize and investigate pressing issues affecting world health today.
- "At the heart of this collaboration lies our commitment to supporting humanitarian causes with our cutting-edge technology platform, driving near-term tangible impact in health equity,” said Maulik Nanavaty, President of Ventures at nference & CEO at Anumana.
Retrieved on:
Tuesday, December 5, 2023
Software,
Research,
Managed Care,
Oncology,
Data Management,
Technology,
Infectious Diseases,
Hospitals,
Artificial Intelligence,
Science,
Biotechnology,
Health,
Confidentiality,
Hope,
Federal Medical Centres,
Cardiology,
Emory University,
Privacy,
Urology,
Data,
Patient,
Multimedia,
DSM-IV codes,
Infection,
Emory Healthcare,
Hospital,
AI,
Geriatrics,
Molina Healthcare,
Pharmaceutical industry Emory Healthcare is comprised of 11 hospitals, the Emory Clinic, and more than 250 provider locations.
Key Points:
- Emory Healthcare is comprised of 11 hospitals, the Emory Clinic, and more than 250 provider locations.
- Emory Healthcare will leverage nference’s state-of-the-art capabilities to securely de-identify health information and provide Emory Healthcare with valuable insights about diseases, treatments, and outcomes for patients.
- “This collaboration with nference allows us to join a federated data network of leading institutions that will enable ground-breaking research.
- De-identified data remains behind firewalls at the source and is only accessible on nSights, maintaining data security and confidentiality.
Retrieved on:
Thursday, October 19, 2023
Cardiology,
Software,
Health,
Artificial Intelligence,
Medical Devices,
Data Management,
Hospitals,
Technology,
FDA,
ECG,
R. Aravamudan,
Interventional cardiology,
Heart,
Automated ECG interpretation,
Multimedia,
Mayo Clinic,
Growth,
Pharmacy,
Partnership,
DSM-IV codes,
Baxter International,
Reema Nanavaty,
University,
Algorithm,
Therapy,
Champaign–Urbana metropolitan area,
Management,
Medical device,
Boston Scientific Anumana, Inc ., a leading AI-driven health technology company and portfolio company of nference , today announced that Maulik Nanavaty has joined Anumana as chief executive officer and member of the Board of Directors.
Key Points:
- Anumana, Inc ., a leading AI-driven health technology company and portfolio company of nference , today announced that Maulik Nanavaty has joined Anumana as chief executive officer and member of the Board of Directors.
- Murali Aravamudan, co-founder of Anumana and nference, has transitioned to executive chairman of the Anumana Board of Directors while continuing as CEO of nference.
- Nanavaty will lead Anumana through a period of growth as the company begins deploying and commercializing its multi-indication ECG-AI platform technology.
- View the full release here: https://www.businesswire.com/news/home/20231019420956/en/
Maulik Nanavaty has joined Anumana as chief executive officer and member of the Board of Directors.
Software,
Research,
Professional Services,
Pharmaceutical,
Data Management,
Technology,
Hospitals,
Data Analytics,
Science,
Biotechnology,
Practice Management,
Health,
Banner Health,
Partnership,
AUC,
Multimedia,
Medicine,
Infection,
Privacy,
Neuroscience,
Patient,
Data,
DSM-IV codes,
Federated,
Diagnosis,
Cardiology,
Medical imaging,
Pharmaceutical industry Banner Health and nference , a science-first software company transforming healthcare by making biomedical data computable, today announced a partnership to accelerate scientific discovery to improve treatment, diagnosis, and care.
Key Points:
- Banner Health and nference , a science-first software company transforming healthcare by making biomedical data computable, today announced a partnership to accelerate scientific discovery to improve treatment, diagnosis, and care.
- The platform provides insights from the deepest, de-identified, multimodal (electronic health record, imaging, electrocardiogram) dataset available across therapeutic areas.
- These include cardiology, oncology, immunology, neuroscience, metabolic diseases, and infectious diseases by leveraging the company’s Federated AI network.
- “Our collaboration with Banner Health is an exciting addition to our unique federated network,” said Murali Aravamudan, co-founder and CEO of nference.
Data Management,
Technology,
University,
Pharmaceutical,
Education,
Oncology,
General Health,
Infectious Diseases,
Artificial Intelligence,
Cardiology,
Science,
Biotechnology,
Software,
Health,
Research,
Informatics,
VUMC,
Drug development,
AUC,
Pathology,
Dean,
Vanderbilt University Medical Center,
Biomedical Research,
Multimedia,
Doctor of Philosophy,
Vanderbilt,
HIV disease progression rates,
MD,
Data,
DSM-IV codes,
Machine learning,
Patient,
Algorithm,
Drug discovery,
Rare,
Vanderbilt University School of Medicine,
Environment,
Glass,
Health information management,
Medical device,
Pharmaceutical industry,
Medical imaging nference , a science-first software company transforming healthcare by making biomedical data computable, and Vanderbilt University Medical Center (VUMC), a leading academic medical center, have announced a strategic agreement aimed at advancing research through the deployment of nference's state-of-the-art federated clinical analytics platform.
Key Points:
- nference , a science-first software company transforming healthcare by making biomedical data computable, and Vanderbilt University Medical Center (VUMC), a leading academic medical center, have announced a strategic agreement aimed at advancing research through the deployment of nference's state-of-the-art federated clinical analytics platform.
- By leveraging the power of federated AI and machine learning, this collaboration will expand clinical insights in key research areas.
- The agreement highlights both nference and VUMC's commitment to using the most advanced technology to accelerate medical research and improve patient care.
- “The depth and longitudinal nature of this high-quality data will provide crucial insights into the complexities of disease progression over time.
Health Technology,
Data Management,
Technology,
Pharmaceutical,
General Health,
Professional Services,
Biometrics,
Hospitals,
Artificial Intelligence,
Biotechnology,
Science,
Software,
Networks,
Other Science,
Data Analytics,
Health,
Vaccine,
White House,
Partnership,
Therapy,
AUC,
SARS-CoV-2,
Public,
Policy,
COVID-19,
Investment company,
NIH,
Parliament of the United Kingdom,
Research,
Radiology,
Bangladesh Technical Education Board,
Marketing,
White,
CDC,
COVID-19 vaccine,
Patient,
Reading East (UK Parliament constituency),
Communication,
ViVe,
Government,
Health information management,
Data science,
Medical device nference, Inc. , a science-first software company transforming healthcare by making biomedical data computable, has been named to Fast Company’s prestigious annual list of the 2023 World’s Most Innovative Companies for its AI-driven software platform delivering insights to accelerate development of therapeutics and diagnostics for life sciences companies.
Key Points:
- nference, Inc. , a science-first software company transforming healthcare by making biomedical data computable, has been named to Fast Company’s prestigious annual list of the 2023 World’s Most Innovative Companies for its AI-driven software platform delivering insights to accelerate development of therapeutics and diagnostics for life sciences companies.
- The award highlights businesses at the forefront of their respective industries, paving the way for the innovations of tomorrow.
- “We are honored to be recognized by the Fast Company as one of the world’s most innovative companies this year,” said Robert Groebel, Vice President, Marketing and Communication, nference.
- nference will also be exhibiting and demonstrating its nSights platform at the 2023 ViVE conference in Nashville, March 26-29, at booth #2603.
Retrieved on:
Wednesday, January 4, 2023
Technology,
Surgery,
Other Health,
Radiology,
Pharmaceutical,
Oncology,
Mental Health,
Medical Devices,
Infectious Diseases,
Clinical Trials,
Science,
Cardiology,
University,
Biotechnology,
Education,
Medical Supplies,
Health,
Practice Management,
Managed Care,
Other Science,
Software,
Research,
Education,
Partnership,
Health,
Health Affairs,
Evidence-based medicine,
Academic health science centre,
Research,
Knowledge,
Multimedia,
Patient,
Faculty,
History,
Duke,
Duke University Health System,
Management,
Pharmaceutical industry Duke Health is building upon its longstanding history of innovative research by joining with nference, a science-first software company, to transform healthcare by making biomedical knowledge computable.
Key Points:
- Duke Health is building upon its longstanding history of innovative research by joining with nference, a science-first software company, to transform healthcare by making biomedical knowledge computable.
- View the full release here: https://www.businesswire.com/news/home/20230104005064/en/
“As an academic health system, Duke Health’s mission is to advance the health of our community through innovation and the rapid translation of groundbreaking research,” said A. Eugene Washington, M.D., chancellor for health affairs at Duke and president and CEO of Duke University Health System.
- “Duke is uniquely positioned to lead efforts in the discovery of new models for care, education, research, and innovation,” said Mary Klotman, M.D., Dean, Duke University School of Medicine, and Vice Chancellor for Health Affairs at Duke.
- “Duke’s world-class faculty, supported by industry-leading technology, can expand research to further address our community’s most pressing health concerns and to eliminate health inequalities.”
The collaboration between Duke and nference will evolve and grow over the coming years providing the advanced tools needed to modernize research and improve patient care.
Cardiology,
Software,
Health,
Artificial Intelligence,
Medical Devices,
Data Management,
Health Technology,
Technology,
Acquisition,
Software,
Cardiac electrophysiology,
Eye,
Mayo Clinic,
UCLA,
FDA,
Deep learning,
Technology,
Brain,
Patient safety,
EP,
Machine learning,
Algorithm,
Heart,
Intelligence,
Electrophysiology,
Academic health science centre,
EGM,
Cardiovascular disease,
ECG,
Roger Hawkins (drummer),
Cardiology,
Partnership,
EMR,
Automated ECG interpretation,
Kidney,
Efficiency,
AI,
Research,
Quality of life,
Safety,
Therapy,
Health,
Medical device,
Medical imaging,
Pramana,
Data The acquisition includes the NeuTrace EP Data Biome platform and a portfolio of AI-enabled EP software applications in development.
Key Points:
- The acquisition includes the NeuTrace EP Data Biome platform and a portfolio of AI-enabled EP software applications in development.
- As part of the transaction, nference acquired rights to the Data Biome platform for uses outside of the cardiovascular field.
- A portfolio of EP applications is under development with the potential to increase procedure accuracy, reduce procedure time, and improve patient safety and outcomes.
- Anumana is pioneering new ground in cardiology AI software solutions that span the entire patient journey, said David McMullin, chief business officer of Anumana.
